Tianjin Med J ›› 2017, Vol. 45 ›› Issue (2): 164-167.doi: 10.11958/20160973
• Experimental Study • Previous Articles Next Articles
HUANG Xue-juan, SU Ke△, LONG Yan, XUN Jing-qiong, WANG Hai-xu
Received:
Revised:
Published:
Online:
Contact:
HUANG Xue-juan, SU Ke△, LONG Yan, XUN Jing-qiong, WANG Hai-xu. Artesunate supresses NF-κB and MCP-1 expressions in high glucose-induced rat mesangial cell proliferation model[J]. Tianjin Med J, 2017, 45(2): 164-167.
Abstract: Objective To investigate the effects of artesunate (Art) on cell proliferation, apoptosis, nuclear factor (NF)- κB and monocyte chemotactic protein 1 (MCP-1) expressions induced by high glucose in rat renal mesangial cells (HBZY- 1), and the mechanism thereof. Methods HBZY-1 cells were cultured and divided into normal glucose group (5.6 mmol/L), high glucose group (25 mmol/L) and high glucose with different concentrations of Art (10 mg/L, 20 mg/L, 30 mg/L) groups. MTT assay was used to detect the cell proliferation after 48 h. The apoptotic rate was evaluated by flow cytometry with Annexin V-FITC/PI double stains. The protein levels of NF-κB and MCP-1 in the cell culture supernatant were determined using ELISA. Results High glucose induced apoptosis and proliferation in HBZY-1 cells, and the expressions of NF-κB and MCP- 1 in the supernatant were also increased (P<0.05). After treatment with Art, the proliferation was obviously abolished, and the apoptosis was increased, and the expressions of NF-κB and MCP-1 in the supernatant were decreased in HBZY- 1 cells. The effects of Art showed a dose- dependent manner (P<0.05). Conclusion Artesunate treatment can reverse the effect of high glucose in HBZY- 1 cells in a dose- dependent manner, which may provide a new therapeutic strategy for diabetic nephropathy.
Key words: diabetic nephropathies, apoptosis, mesangial cells, NF- kappa B, monocyte chemotactic protein 1, Artesunate
/ Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.tjyybjb.ac.cn/EN/10.11958/20160973
https://www.tjyybjb.ac.cn/EN/Y2017/V45/I2/164